Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health Services Inc. has demonstrated robust performance, particularly in its OP Rehab and Pharmacy Solutions segments, with Specialty revenue reaching approximately $2.6 billion in 2025, reflecting a 43% year-over-year growth and an improved EBITDA margin. The strategic acquisition of Amedisys and LHC has enhanced the Provider division's geographic reach, contributing to a 15% year-over-year increase in home health average daily census in 4Q:25, while stable reimbursement trends support continued growth. Furthermore, BrightSpring's focus on leveraging specialty drug spend, projected to grow at a compound annual growth rate of 10%-15%, positions the company favorably within its market, fostering the potential for increased generic drug market share and significant EBITDA enhancement in the years ahead.

Bears say

The financial outlook for BrightSpring Health Services Inc. is negatively impacted by potential weakening in client budgets, which could adversely affect business and revenue generation, particularly within its Pharmacy Solutions segment. Additionally, the company faces risks related to reduced prescription writing by healthcare professionals and diminished drug utilization, both of which could negatively impact revenues, operating results, and cash flows. Furthermore, the significant debt burden may constrain BrightSpring Health's ability to invest in growth initiatives, limiting potential expansion opportunities despite the acquisition of additional home health locations.

BTSG has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 9 analysts, BTSG has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.